Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $42.02.Don't Miss Our ...

4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual ...

Verona Pharma is a clinical stage, pre-revenue, biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet ...

Glenmede Trust Co. NA lowered its stake in Verona Pharma plc (NASDAQ:VRNA – Free Report) by 13.1% during the 3rd quarter, ...

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...

European equities traded in the US as American depositary receipts were trending slightly lower late Monday morning, declining 0.16% to 1,278.01 on the S&P Europe Select ADR Index. From continental ...

Verona Pharma recently got approval for ensifentrine in COPD. Ensifentrine has a differentiated MoA and superior safety profile. Despite a diverse market, Verona will find its own place here.

While not every stock... Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently ...

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial.

On Oct. 22, Caligan announced that it has taken a position in Verona Pharma. Verona Pharma is a clinical stage, pre-revenue, biopharmaceutical company that focuses on the development and ...

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...